{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:13:17Z","timestamp":1792548797593,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007710","name":"University of Connecticut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jaad.2017.10.012","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T16:47:27Z","timestamp":1508172447000},"page":"323-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry"],"prefix":"10.1016","volume":"78","author":[{"given":"Bruce","family":"Strober","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Karki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey H.","family":"Holmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2017.10.012_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3 Pt 1","key":"10.1016\/j.jaad.2017.10.012_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.10.012_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.10.012_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaad.2004.04.014","article-title":"Determinants of quality of life in patients with psoriasis: a study from the US population","volume":"51","author":"Gelfand","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.10.012_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study","volume":"157","author":"Gisondi","year":"2007","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.10.012_bib6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.10.012_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.10.012_bib8","doi-asserted-by":"crossref","first-page":"f5961","DOI":"10.1136\/bmj.f5961","article-title":"Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study","volume":"347","author":"Wan","year":"2013","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jaad.2017.10.012_bib9","first-page":"1210","article-title":"PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents","volume":"11","author":"Papp","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"5 Suppl 101","key":"10.1016\/j.jaad.2017.10.012_bib10","first-page":"S96","article-title":"The Corrona US registry of rheumatic and autoimmune diseases","volume":"34","author":"Kremer","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.10.012_bib11","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.jaad.2017.10.012_bib12","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arth Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2017.10.012_bib13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2017.10.012_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/annrheumdis-2013-203936","article-title":"The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor","volume":"74","author":"Harrold","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jaad.2017.10.012_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha\u00a0agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arth Rheum"},{"issue":"1","key":"10.1016\/j.jaad.2017.10.012_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.10.012_bib17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2011.06.011","article-title":"Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials","volume":"66","author":"Lebwohl","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.10.012_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2017.10.012_bib19","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","article-title":"Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"30","author":"Menter","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2017.10.012_bib20","first-page":"48","article-title":"German psoriasis registry PsoBest: objectives, methodology and baseline data","volume":"12","author":"Augustin","year":"2014","journal-title":"J\u00a0Dtsch Dermatol Ges"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217325380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217325380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:44:20Z","timestamp":1759272260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217325380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0190962217325380"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.10.012","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}